Education
About Us
Working with TipRanks
Follow Us
Celcuity (CELC)
NASDAQ:CELC
CELC Stock Chart & Stats
Day’s Range― - ―
52-Week Range$7.58 - $19.77
Previous CloseN/A
Volume14.25K
Average Volume (3M)148.25K
Market Cap
$474.84M
Enterprise Value$226.68M
Total Cash (Recent Filing)$16.48M
Total Debt (Recent Filing)$182.00K
Price to Earnings (P/E)―
Beta1.33
Next Earnings
Aug 07, 2025EPS Estimate
-0.88Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.86
Shares Outstanding37,866,360
10 Day Avg. Volume183,862
30 Day Avg. Volume148,248
Financial Highlights & Ratios
PEG Ratio-0.30
Price to Book (P/B)1.61
Price to Sales (P/S)0.00
P/FCF Ratio-5.97
Enterprise Value/Market Cap0.48
Enterprise Value/Revenue493.54
Enterprise Value/Gross Profit-7.29K
Enterprise Value/Ebitda-0.60
Forecast
1Y Price Target
$27.75Price Target Upside107.87% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering6
Celcuity News
PremiumCompany Announcements
Celcuity Announces Promising Phase 1 Gedatolisib Results
PremiumCompany Announcements
Celcuity Approves Stock Plan Amendment at Annual Meeting
PremiumCompany Announcements
Celcuity Inc. Earnings Call: Balancing Progress and Challenges
Bulls Say, Bears Say
Bulls Say
Clinical Trial ProgressThere is a positive bias heading into the readout based on strong Phase I data for gedatolisib.
Drug Application And ApprovalThe company intends to use positive topline data to support a new drug application (NDA) filing to pursue commercial approval.
Financial StabilityCELC had cash and cash equivalents of $206M, believed to be sufficient to fund operations through 2026.
Bears Say
Market SentimentShort interest is at 10.2% of the float, indicating a significant portion of investors may be betting against the stock.
Revenue ProjectionsFor 2025, projections indicate no revenues and a net loss of $3.92 per diluted share.
Study Data ConcernsConcerns have been raised around the EMBER-3 dataset, including a relatively high proportion of 1L and bone-only disease patients, and no 3L patients in the dataset that can be identified.
Options Prices
Currently, No data available
---
Ownership Overview
12.27% Insiders
11.94% Mutual Funds
53.28% Other Institutional Investors
14.20% Public Companies and Individual Investors
CELC FAQ
What was Celcuity’s price range in the past 12 months?
Celcuity lowest stock price was $7.58 and its highest was $19.77 in the past 12 months.
What is Celcuity’s market cap?
Celcuity’s market cap is $474.84M.
When is Celcuity’s upcoming earnings report date?
Celcuity’s upcoming earnings report date is Aug 07, 2025 which is in 37 days.
How were Celcuity’s earnings last quarter?
Celcuity released its earnings results on May 14, 2025. The company reported -$0.86 earnings per share for the quarter, missing the consensus estimate of N/A by -$0.86.
Is Celcuity overvalued?
According to Wall Street analysts Celcuity’s price is currently Undervalued.
Does Celcuity pay dividends?
Celcuity does not currently pay dividends.
What is Celcuity’s EPS estimate?
Celcuity’s EPS estimate is -0.88.
How many shares outstanding does Celcuity have?
Celcuity has 37,866,360 shares outstanding.
What happened to Celcuity’s price movement after its last earnings report?
Celcuity reported an EPS of -$0.86 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went down -3.131%.
Which hedge fund is a major shareholder of Celcuity?
Currently, no hedge funds are holding shares in CELC
Celcuity Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$27.75 (107.87% Upside)
$27.75 (107.87% Upside)
Blogger Sentiment
Bullish
CELC Sentiment 100%
Sector Average 71%
Sector Average 71%
Hedge Fund Trend
Increased
By 1.5M Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Negative
Last 7 Days ▼ 4.8%
Last 30 Days ▼ 1.2%
Last 30 Days ▼ 1.2%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-22.92%
12-Months-Change
Fundamentals
Return on Equity
-115.39%
Trailing 12-Months
Asset Growth
15.91%
Trailing 12-Months
Company Description
Celcuity
Celcuity Inc., a clinical stage biotechnology company, focuses on the development of molecularly targeted therapies for cancer patients in the United States. The company's CELsignia diagnostic platform uses a patient's living tumor cells to identify the specific abnormal cellular process driving a patient's cancer and the related targeted therapy for the treatment. Its drug candidate includes Gedatolisib, which selectively targets various class I isoforms of PI3K and mammalian target of rapamycin and focus on the treatment of patients with hormone receptor positive, HER2-negative, and advanced or metastatic breast cancer. The company is also developing CELsignia MP test, a qualitative laboratory developed test that measures HER2, c-Met, and PI3K signaling activity in breast and ovarian tumor cells. It had a license agreement with Pfizer, Inc. for the development and commercialization rights to Gedatolisib. Celcuity Inc. was founded in 2011 and is headquartered in Minneapolis, Minnesota.
CELC Earnings Call
Q1 2025
0:00 / 0:00
Earnings Call Sentiment|Neutral
The earnings call reflects a mix of positive developments in clinical trials and potential market opportunities, contrasted by increased financial losses and operational cash burn. The anticipation for upcoming data readouts is high, but there are concerns about financial sustainability.Read More>CELC Stock 12 Month Forecast
Average Price Target
$27.75
▲(107.87%Upside)
Technical Analysis
Altimmune
―
Autolus Therapeutics
―
Oric Pharmaceuticals
―
Abivax SA Sponsored ADR
―
Rapport Therapeutics, Inc.
―